[6-K] Redhill Biopharma Ltd. Current Report (Foreign Issuer)
RedHill Biopharma disclosed it is not in compliance with Nasdaq Listing Rule 5550(b), which requires minimum stockholders' equity of $2,500,000. Nasdaq notified the Company of the deficiency on April 15, 2025 and on August 8, 2025 granted an extension giving the Company until October 13, 2025 to regain compliance.
The Company has submitted a plan to Nasdaq to restore compliance; if it does not meet the requirement by the extension date it may appeal to a Hearings Panel for additional time. The filing also notes that forward-looking statements about achieving compliance depend on market conditions and the satisfaction and closing of financing arrangements referenced in other filings.
RedHill Biopharma ha comunicato di non essere conforme alla Nasdaq Listing Rule 5550(b), che richiede un patrimonio netto minimo di $2,500,000. Nasdaq ha informato la Societ脿 della non conformit脿 il 15 aprile 2025 e, il 8 agosto 2025, ha concesso una proroga fino al 13 ottobre 2025 per ristabilire la conformit脿.
La Societ脿 ha presentato a Nasdaq un piano per ripristinare la conformit脿; se non dovesse soddisfare il requisito entro la scadenza, potr脿 presentare ricorso a un Hearings Panel per ottenere ulteriore tempo. Il documento precisa inoltre che le dichiarazioni prospettiche sul raggiungimento della conformit脿 dipendono dalle condizioni di mercato e dalla realizzazione e chiusura degli accordi di finanziamento citati in altri atti.
RedHill Biopharma comunic贸 que no cumple con la Regla de Cotizaci贸n de Nasdaq 5550(b), que exige un patrimonio neto m铆nimo de $2,500,000. Nasdaq notific贸 a la Compa帽铆a de la deficiencia el 15 de abril de 2025 y, el 8 de agosto de 2025, le concedi贸 una pr贸rroga hasta el 13 de octubre de 2025 para recuperar la conformidad.
La Compa帽铆a present贸 a Nasdaq un plan para restaurar la conformidad; si no cumple el requisito antes de la fecha de pr贸rroga, podr谩 apelar ante un Hearings Panel para solicitar tiempo adicional. La presentaci贸n tambi茅n indica que las declaraciones prospectivas sobre la obtenci贸n de la conformidad dependen de las condiciones de mercado y del cumplimiento y cierre de los acuerdos de financiaci贸n mencionados en otras presentaciones.
RedHill Biopharma電� 雮橃姢雼� 靸侅灔 攴滌爼 5550(b)鞐� 霐半ジ 鞖旉贝鞚� 於╈”頃橃 氇豁晿瓿� 鞛堨潓鞚� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 攴滌爼鞚� 斓滌唽 欤检＜鞛愲掣鞙茧 $2,500,000鞚� 鞖旉惮頃╇媹雼�. 雮橃姢雼レ潃 鞚� 攵堨澊頄� 靷嫟鞚� 2025雲� 4鞗� 15鞚�鞐� 韱奠頄堨溂氅�, 2025雲� 8鞗� 8鞚�鞐愲姅 鞁滌爼 旮瓣皠鞚� 鞐办灔頃橃棳 2025雲� 10鞗� 13鞚�旯岇 欷�靾橂ゼ 須岆车頃橂弰搿� 頄堨姷雼堧嫟.
須岇偓電� 雮橃姢雼レ棎 鞁滌爼 瓿勴殟鞚� 鞝滌稖頄堨溂氅�, 鞐办灔 旮绊暅旯岇 鞖旉贝鞚� 於╈”頃橃 氇豁暊 瓴届毎 於旉皜 鞁滉皠鞚� 鞏魂赴 鞙勴暣 Hearings Panel鞐� 頃唽頃� 靾� 鞛堨姷雼堧嫟. 瓿奠嫓靹滊姅 霕愴暅 欷�靾� 雼劚鞐� 甏�頃� 鞝勲靹� 歆勳垹鞚� 鞁滌灔 靸來櫓瓿� 雼るジ 靹滊鞐� 鞏戈笁霅� 鞛愱笀 臁半嫭 鞎届爼鞚� 靹膘偓 氚� 膦呹舶 鞐秬鞐� 雼牑 鞛堧嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
RedHill Biopharma a d茅clar茅 ne pas 锚tre en conformit茅 avec la r猫gle d'inscription Nasdaq 5550(b), qui exige des capitaux propres minimums de $2,500,000. Nasdaq a inform茅 la Soci茅t茅 de cette non-conformit茅 le 15 avril 2025 et, le 8 ao没t 2025, a accord茅 une prolongation jusqu'au 13 octobre 2025 pour retrouver la conformit茅.
La Soci茅t茅 a soumis 脿 Nasdaq un plan visant 脿 r茅tablir la conformit茅 ; si elle ne respecte pas l'exigence d'ici la date de prolongation, elle peut faire appel 脿 un Hearings Panel pour obtenir un d茅lai suppl茅mentaire. Le d茅p么t signale 茅galement que les d茅clarations prospectives concernant l'obtention de la conformit茅 d茅pendent des conditions de march茅 et de la r茅alisation et de la cl么ture des accords de financement mentionn茅s dans d'autres documents.
RedHill Biopharma gab bekannt, dass es die Nasdaq-Listingregel 5550(b) nicht erf眉llt, die ein Mindest-Eigenkapital von $2,500,000 verlangt. Nasdaq hat das Unternehmen am 15. April 2025 眉ber die Nichteinhaltung informiert und am 8. August 2025 eine Fristverl盲ngerung bis zum 13. Oktober 2025 gew盲hrt, um die Compliance wiederherzustellen.
Das Unternehmen hat Nasdaq einen Plan zur Wiederherstellung der Compliance vorgelegt; sollte die Anforderung bis zum Fristende nicht erf眉llt werden, kann es beim Hearings Panel um zus盲tzliche Zeit ersuchen. Die Einreichung weist zudem darauf hin, dass zukunftsgerichtete Aussagen zum Erreichen der Compliance von den Marktbedingungen sowie vom Zustandekommen und Abschluss der in anderen Unterlagen genannten Finanzierungsvereinbarungen abh盲ngen.
- Nasdaq granted an extension until October 13, 2025 to regain compliance
- The Company submitted a plan to Nasdaq to address the deficiency
- Non-compliance with Nasdaq Listing Rule 5550(b) due to stockholders' equity below $2,500,000
- Potential delisting risk if the Company does not regain compliance by the deadline
- Plans to regain compliance depend on financing and market conditions described elsewhere, creating execution risk
Insights
TL;DR: Nasdaq equity deficiency is a material negative; the extension provides runway but delisting risk remains without clear financing.
The company鈥檚 failure to meet the $2.5 million stockholders鈥� equity threshold is a material listing compliance issue. Nasdaq鈥檚 extension to October 13, 2025 is remedial but time-limited; the registrant鈥檚 path to compliance appears to rely on financing arrangements referenced elsewhere, which carry execution and market risks. If financing does not close or equity is not restored, the Company faces appeal processes or potential delisting, which would materially affect shareholder liquidity and valuation.
TL;DR: The Company followed prescribed procedures by submitting a plan and obtaining an extension; governance processes are operating but reflect financial strain.
RedHill engaged with Nasdaq, submitted a remediation plan and obtained an extension, which is consistent with standard compliance remediation practices. The availability of an appeal to a Hearings Panel offers an additional procedural safeguard. However, these steps underscore an underlying capital shortfall and dependency on successful financing or other equity-restoring measures disclosed elsewhere in the Company鈥檚 filings.
RedHill Biopharma ha comunicato di non essere conforme alla Nasdaq Listing Rule 5550(b), che richiede un patrimonio netto minimo di $2,500,000. Nasdaq ha informato la Societ脿 della non conformit脿 il 15 aprile 2025 e, il 8 agosto 2025, ha concesso una proroga fino al 13 ottobre 2025 per ristabilire la conformit脿.
La Societ脿 ha presentato a Nasdaq un piano per ripristinare la conformit脿; se non dovesse soddisfare il requisito entro la scadenza, potr脿 presentare ricorso a un Hearings Panel per ottenere ulteriore tempo. Il documento precisa inoltre che le dichiarazioni prospettiche sul raggiungimento della conformit脿 dipendono dalle condizioni di mercato e dalla realizzazione e chiusura degli accordi di finanziamento citati in altri atti.
RedHill Biopharma comunic贸 que no cumple con la Regla de Cotizaci贸n de Nasdaq 5550(b), que exige un patrimonio neto m铆nimo de $2,500,000. Nasdaq notific贸 a la Compa帽铆a de la deficiencia el 15 de abril de 2025 y, el 8 de agosto de 2025, le concedi贸 una pr贸rroga hasta el 13 de octubre de 2025 para recuperar la conformidad.
La Compa帽铆a present贸 a Nasdaq un plan para restaurar la conformidad; si no cumple el requisito antes de la fecha de pr贸rroga, podr谩 apelar ante un Hearings Panel para solicitar tiempo adicional. La presentaci贸n tambi茅n indica que las declaraciones prospectivas sobre la obtenci贸n de la conformidad dependen de las condiciones de mercado y del cumplimiento y cierre de los acuerdos de financiaci贸n mencionados en otras presentaciones.
RedHill Biopharma電� 雮橃姢雼� 靸侅灔 攴滌爼 5550(b)鞐� 霐半ジ 鞖旉贝鞚� 於╈”頃橃 氇豁晿瓿� 鞛堨潓鞚� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 攴滌爼鞚� 斓滌唽 欤检＜鞛愲掣鞙茧 $2,500,000鞚� 鞖旉惮頃╇媹雼�. 雮橃姢雼レ潃 鞚� 攵堨澊頄� 靷嫟鞚� 2025雲� 4鞗� 15鞚�鞐� 韱奠頄堨溂氅�, 2025雲� 8鞗� 8鞚�鞐愲姅 鞁滌爼 旮瓣皠鞚� 鞐办灔頃橃棳 2025雲� 10鞗� 13鞚�旯岇 欷�靾橂ゼ 須岆车頃橂弰搿� 頄堨姷雼堧嫟.
須岇偓電� 雮橃姢雼レ棎 鞁滌爼 瓿勴殟鞚� 鞝滌稖頄堨溂氅�, 鞐办灔 旮绊暅旯岇 鞖旉贝鞚� 於╈”頃橃 氇豁暊 瓴届毎 於旉皜 鞁滉皠鞚� 鞏魂赴 鞙勴暣 Hearings Panel鞐� 頃唽頃� 靾� 鞛堨姷雼堧嫟. 瓿奠嫓靹滊姅 霕愴暅 欷�靾� 雼劚鞐� 甏�頃� 鞝勲靹� 歆勳垹鞚� 鞁滌灔 靸來櫓瓿� 雼るジ 靹滊鞐� 鞏戈笁霅� 鞛愱笀 臁半嫭 鞎届爼鞚� 靹膘偓 氚� 膦呹舶 鞐秬鞐� 雼牑 鞛堧嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
RedHill Biopharma a d茅clar茅 ne pas 锚tre en conformit茅 avec la r猫gle d'inscription Nasdaq 5550(b), qui exige des capitaux propres minimums de $2,500,000. Nasdaq a inform茅 la Soci茅t茅 de cette non-conformit茅 le 15 avril 2025 et, le 8 ao没t 2025, a accord茅 une prolongation jusqu'au 13 octobre 2025 pour retrouver la conformit茅.
La Soci茅t茅 a soumis 脿 Nasdaq un plan visant 脿 r茅tablir la conformit茅 ; si elle ne respecte pas l'exigence d'ici la date de prolongation, elle peut faire appel 脿 un Hearings Panel pour obtenir un d茅lai suppl茅mentaire. Le d茅p么t signale 茅galement que les d茅clarations prospectives concernant l'obtention de la conformit茅 d茅pendent des conditions de march茅 et de la r茅alisation et de la cl么ture des accords de financement mentionn茅s dans d'autres documents.
RedHill Biopharma gab bekannt, dass es die Nasdaq-Listingregel 5550(b) nicht erf眉llt, die ein Mindest-Eigenkapital von $2,500,000 verlangt. Nasdaq hat das Unternehmen am 15. April 2025 眉ber die Nichteinhaltung informiert und am 8. August 2025 eine Fristverl盲ngerung bis zum 13. Oktober 2025 gew盲hrt, um die Compliance wiederherzustellen.
Das Unternehmen hat Nasdaq einen Plan zur Wiederherstellung der Compliance vorgelegt; sollte die Anforderung bis zum Fristende nicht erf眉llt werden, kann es beim Hearings Panel um zus盲tzliche Zeit ersuchen. Die Einreichung weist zudem darauf hin, dass zukunftsgerichtete Aussagen zum Erreichen der Compliance von den Marktbedingungen sowie vom Zustandekommen und Abschluss der in anderen Unterlagen genannten Finanzierungsvereinbarungen abh盲ngen.
FAQ
What compliance issue does RedHill Biopharma (RDHL) report?
What extension did Nasdaq grant to RDHL and when?
What will happen if RDHL does not regain compliance by the deadline?
Does the filing include financial results or transaction details?
Are there risks associated with RDHL鈥檚 plan to regain compliance?
